Enzalutamide

(Xtandi®)

Xtandi®

Drug updated on 11/9/2023

Dosage FormCapsule (oral; 40 mg); Tablet (oral; 40 mg, 80 mg)
Drug ClassAndrogen receptor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer

Product Monograph / Prescribing Information

Document TitleYearSource
Xtandi (enzalutamide) Prescribing Information.2022Astellas Pharma US Inc., Northbrook, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review. 2023Frontiers in Endocrinology
The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. 2023Journal of cancer research and therapeutics
A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens. 2023Anticancer Drugs
Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review. 2023Future Oncology
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review. 2023Therapeutic advances in Medical Oncology
Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.2023European Urology Oncology
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis.2022Minerva Urology and Nephrology
Association of novel androgen receptor axis-targeted therapies with diarrhea in patients with prostate cancer: a Bayesian network analysis. 2022Frontiers in Medicine
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. 2022Journal of the National Cancer Institute
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. 2022Anti-Cancer Drugs
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: a systematic review. 2022Urologic Oncology: Seminars and Original Investigations
Assessment report: Xtandi. 2021EMA
Enzalutamide for treating hormone-sensitive metastatic prostate cancer. 2021NICE
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. 2021Prostate Cancer and Prostatic Diseases
Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021Frontiers in Oncology
Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: a systematic review. 2021Journal of Geriatric Oncology
Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.2021Frontiers in Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021Prostate Cancer and Prostatic Diseases
Final clinical guidance report: enzalutamide (Xtandi).2020CADTH
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis.2020International Journal of Clinical Oncology
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. 2020Prostate Cancer and Prostatic Diseases
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. 2020Journal of Oncology Pharmacy Practice
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. 2020Prostate Cancer and Prostatic Diseases
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis.2020Journal of Pharmacy and Pharmaceutical Sciences
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer.2019Medicine
Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value.2018ICER
Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer.2018Value in Health

Clinical Practice Guidelines